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MicroRNAs are small, noncoding RNA molecules that regulate target gene expression in the posttranscriptional level. Unlike
siRNA, microRNAs are “fine-tuners” rather than “switches” in the regulation of gene expression; thus they play key roles in
maintaining tissue homeostasis.The aberrant microRNA expression is implicated in the disease process. To date, numerous studies
have demonstrated the regulatory roles ofmicroRNAs in various pathophysiological conditions. In contrast, the study ofmicroRNA
in pregnancy and its associated complications, such as preeclampsia (PE), fetal growth restriction (FGR), and preterm labor, is a
young field. Over the last decade, the knowledge of pregnancy-related microRNAs has increased and the molecular mechanisms
by which microRNAs regulate pregnancy or its associated complications are emerging. In this review, we focus on the recent
advances in the research of pregnancy-related microRNAs, especially their function in pregnancy-associated complications and
the potential clinical applications. Here microRNAs that associate with pregnancy are classified as placenta-specific, placenta-
associated, placenta-derived circulating, and uterinemicroRNA according to their localization and origin.MicroRNAs offer a great
potential for developing diagnostic and therapeutic targets in pregnancy-related disorders.
1. Introduction
RNA is a single-stranded genetic material involved in various
biological roles including coding and decoding, regulation
of gene expression, and protein synthesis. Noncoding RNAs
(ncRNA) that are not translated into protein form a large
portion of total cellular RNA (95–98%).The ncRNAs include
some highly abundant RNAs, such as transfer RNA (tRNA)
and ribosomal RNA (rRNA), and functionally important
RNAs, including long ncRNA and microRNA (miRNA)
[1, 2]. Typically, miRNAs are transcribed from miRNA
genes by RNA polymerase II or III in the nucleus. The
primary transcripts of miRNA genes (pri-miRNA) are single-
stranded RNA molecules composing several hundred RNA
nucleotides and one or more stem-loop structures. Subse-
quently, the stem-loop structure is recognized and processed
by a protein complex containing ribonuclease Drosha and
double-stranded RNA binding protein DGCR8 to form
precursor miRNA (pre-miRNA) [3]. Next, the pre-miRNAs
are exported into cytoplasm by exportin 5 utilizing the
energy provided by Ran- (ras-related nuclear protein-) GTP
complex. In the cytoplasm, the loop and part of the stem
structure of pre-miRNA are cleaved by Dicer to form
a double-stranded RNA (dsRNA) molecule with 19–25
nucleotides [4]. Finally, the dsRNA dissociates into two
single-stranded RNAs (ssRNA) with the help of helicase and
the ssRNAs subsequently integrate into the RNA-induced
silencing complex (RISC), including Dicer, transactivation
response RNA binding protein (TRBP), and Argonaute 2
(Ago 2), to target downstream messenger RNA (mRNA) by
incomplete alignment [5]. Functionally, the miRNA-RISC
inhibits target mRNA expression through either translational
repression or mRNA cleavage (Figure 1). Notably, miRNAs in
human are estimated to target well over 60% of total coding
genes [6]. So far, more than 1000 and at least 303 mature
miRNAs were discovered from human and mouse genomes,
respectively [7, 8]. Given the broad range of miRNA targets
in the cell, it is no surprise that miRNAs regulate many
physiological and pathological processes [9–11].
Placenta and uterus are themajor organs in pregnancy. Of
the two, placenta is the most important one and is associated
with many pregnancy-related disorders. Placenta facilitates
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Figure 1: A schematic diagram showing miRNA biogenesis and miRNA-mediated target mRNA suppression. The primary miRNAs (pri-
miRNA) are transcribed frommiRNA genes by RNA polymerase II or III in the nucleus and subsequently processed by Drosha and DGCR8
to form precursor miRNA (pre-miRNA). Next, the pre-miRNAs are exported into cytoplasm by exportin 5 and RanGTP. In the cytoplasm,
the pre-miRNAs are further cleaved by Dicer and resulted in two ssRNAs. Finally, the ssRNAs integrate into RISC protein complex which
includesArgonaute 2, Dicer, andTRBP. Functionally, themiRNA-RISC complex inhibits targetmRNAexpression through either translational
repression or mRNA cleavage.
nutrient uptake and gaseous exchange to the developing
fetus. It regulates temperature, produces hormones, and
provides protection from internal infections during preg-
nancy. Placenta is mainly composed of trophoblasts, decidual
cells, endothelial cells, and mesenchymal cells. The cellular
activities of these cells, such as trophoblast proliferation,
differentiation, and invasion, as well as mesenchymal cell
differentiation, decidualization, and angiogenesis, are pivotal
for a healthy pregnancy [12, 13]. Moreover, pregnancy is an
altered physiological condition regulated by genetic (e.g.,
maternal inherited genes), environmental (e.g., nutrition),
and physiological (e.g., inflammation, hypoxia) factors.Many
studies suggest that miRNA expression is altered due to the
response to these changes [14–16]. Thus, we propose that
miRNAs respond to the change of physiological condition
during pregnancy and facilitate successful pregnancy process,
whereas dysregulation of miRNAs causes or contributes to
disorders of pregnancy (Figure 2).
2. MicroRNA in Pregnancy Regulation
The importance of miRNA in the regulation of pregnancy
has been proved by knocking down Dicer in mouse model
or human tissue. Deletion of Dicer caused hypotrophy and
disorganization of uterus and oviduct which subsequently
resulted in female sterility [17]. Interestingly, global reduction
ofmiRNA caused by the deletion of Dicer in human placental
explants enhanced cytotrophoblast proliferation by activating
promitogenic signaling pathways [18].
A large number of miRNAs have been identified to be
associated with pregnancy and its disorders using quanti-
tative PCR, microarray, or deep sequencing profiling [19–
21]. These miRNAs can be classified as tissue-resident and
circulating miRNA, based on their physiological localization
and transportation method. The tissue-resident miRNAs
locate in the tissue where they are being synthesized and
regulate target genes locally, whereas circulating microRNAs
are released into the blood via exosome and transported to
other cell/tissue types to regulate target genes in a paracrine
or telecrine action [22]. In pregnancy, since the placenta
and uterus are the main pregnancy-related organs, tissue-
resident miRNAs discussed in this review include placental
(placenta-specific and associated) as well as a small group of
uterine miRNAs (Table 1). This review will mainly focus on
the recent progress of miRNAs in pregnancy-related com-
plications, such as pregnancy loss, preeclampsia, intrauterine
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Figure 2:Thepregnancy process is regulated by genetic, environmental, and physiological factors.MiRNAs in the placenta anduterus respond
to the change of these factors during pregnancy. Altered expression of miRNAs leads to the pregnancy disorders.
growth restriction/fetal growth restriction (IUGR/FGR), and
preterm birth. Circulating miRNAs released from placenta
will be discussed briefly due to limited literature. Moreover,
the fetomaternal miRNA exchange and its role in the preg-
nancy regulation will also be mentioned.
3. Placental MicroRNA
There seems to be a confusion in the literature on the
terminology and we will clarify it here. Typically, placen-
tal miRNAs include placenta-specific, placenta-associated,
and placenta-derived circulating miRNAs. While placenta-
specific miRNAs are expressed largely or uniquely in the
placental tissue, placenta-associated miRNAs are expressed
ubiquitously in the placenta and other tissues. Placenta-
derived circulating miRNAs refer to the placenta-released
circulating miRNA. Considering that placenta is a central
organ for healthy pregnancy, studies regarding the placental
miRNAs are important to understand the regulatory mecha-
nisms of normal and complicated pregnancies [96].
3.1. Placenta-Specific MicroRNA. The observation of placen-
ta-enriched miRNAs, miR-141, miR-23a, and miR-136, was
first reported in 2004 [23]. Benefitting from a large-scale
small RNA library sequencing, placenta-specific/enriched
miRNAs have been proved to be abundant (∼100) in the
mammalian genome [7, 29]. Interestingly, many of these
placenta-specific miRNAs are closely located on their
respective chromosomes as a cluster and are regulated by the
same promoter. C19MC, a cluster on chromosome 19, was
first identified in 2009 [97], followed by C14MC, a cluster on
chromosome 14, and miR-371-3 cluster, also on chromosome
19 [26]. Expression of C19MC members is largely restricted
in the reproductive system and placenta [29, 30]. Similarly,
C14MC accommodates 52 miRNA genes in about 40 kb
region and the expression of members is abundant in
developing embryo and placental tissue [26], whereas miR-
371-3 cluster only has 3 main members and is prominently
expressed in the placenta [33]. Surprisingly, some placenta-
specific miRNA clusters can be located even within a single
gene intron. The Sfmbt2 cluster, which is located in the
10th intron of Sfmbt2 gene, has 36 distinct miRNAs which
are abundantly expressed in the embryonic stem cells and
placenta [98]. In addition, some placenta-specific miRNAs,
located in different chromosomes, are derived from the same
transposon. For example, miR-1302 family, which comprises
58 orthologs, is derived from MER53 transposon and is only
found in the mammalian placenta [35].
3.1.1. Placenta-Specific MicroRNA Regulates Pregnancy Pro-
cess. Placenta-specific miRNAs have long been proposed for
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Table 1: A brief list of pregnancy-related microRNAs.
MicroRNA name Function relates to pregnancy Reference
Placenta-specific microRNA
miR-23a, miR-136,
and miR-141
Enriched in placenta; trophoblast cell proliferation; target pleiomorphic adenoma
gene 1 (PLAG1) [23–25]
C14MC cluster Abundant in developing embryo and placenta [26]
C19MC cluster
(miR-516, 517, 518, 519,
etc.)
Expression restricted in reproductive system and placenta; trophoblast cell
invasion, migration; implicated in complete hydatidiform moles (CHM), fetal
growth restriction (FGR)
[27–32]
miR-371, miR-372,
and miR-373 Predominantly expressed in placenta [33]
miR-675 Inhibits embryonic and extraembryonic cell lines proliferation [34]
miR-1302 family Found in mammal placenta [35]
Placenta-associated microRNA
Let-7 Regulates NF-𝜅B pathway and IL-6 [36]
miR-15a, miR-15b Regulates angiogenesis and is increased in preeclampsia; differentially expressedin preterm birth placenta [37, 38]
miR-16, miR-21, and
miR-146a
Downregulated in response to smoke exposure, angiogenesis-associated, and
decreased in the small for gestation (SGA) placentas [39, 40]
miR-17∼92 cluster Regulate syncytiotrophoblast differentiation [41]
miR-17, miR-27, and
miR-92
Differentially expressed in gestation age; downregulated in early pregnancy loss
placenta [42, 43]
miR-17, miR-20a, and
miR-20b Increased in preeclampsia and regulate hydrogen sulphide (H2S) [44, 45]
miR-18a Inhibits invasion and promotes apoptosis of trophoblast cells [46]
miR-19b Downregulated in early pregnancy loss placenta [43]
miR-27a, miR-199b,
and miR-429 Regulate renin-angiotensin system to help placenta adapt to hypoxia [47]
miR-29b Regulates apoptosis, invasion, and angiogenesis of trophoblast cells [48]
miR-30a Attenuates mesenchymal stem cells (MSCs) mediated immune response inpreeclampsia [44]
miR-34a It is decreased in placenta accreta patients; and suppression of miR-34a increasedtrophoblast invasion [49]
miR-93, miR-205,
miR-224, miR-335,
miR-424, miR-451,
miR-491
Differentially expressed in primary trophoblasts exposed to hypoxia and
downregulate eNOS (miR-335) [50, 51]
miR-101 Regulates apoptosis of trophoblast cells [52]
miR-126 Proangiogenic factor and decreased in preeclampsia [53]
miR-133a Overexpressed in recurrent spontaneous abortion (RSA) and downregulateshuman leukocyte antigen (HLA)-G [54]
miR-137 Affects proliferation and migration of placenta trophoblast cells [55]
miR-148/152 family Inhibits IL-12, IL-6, and TNF-𝛼 and mediates immune tolerance; regulates HLA-G [56, 57]
miR-155
Regulates trophoblast function, including proliferation, migration, invasion, and
differentiation; downregulates angiogenic factors and implicated in preeclampsia;
targets angiotensin II type 1 receptor; modulates eNOS expression
[58–62]
miR-181
Regulates TGF-𝛽 pathway and IL-6; attenuates the immunosuppressive properties
in placenta; inhibits proliferation and immunosuppressive properties of MSCs; is
differentially expressed in preterm birth placenta
[37, 63]
miR-195 Altered expression in preeclampsia; affects trophoblast cell invasion [31, 64–67]
miR-210
Increased expression in response to the hypoxic placenta; regulates trophoblast
cell migration and invasion; modulates mitochondrial respiration in placenta;
targets critical steroidogenetic enzyme; modulates inflammation-related pathway,
potassium channel modulatory factor, and thrombospondin; increased in FGR;
differentially expressed in preterm birth placenta
[37, 68–75]
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Table 1: Continued.
MicroRNA name Function relates to pregnancy Reference
miR-325 Elevated in preeclampsia and correlates with blood pressure [76]
miR-376c Promotes trophoblast cell proliferation and invasion [77]
miR-378a-5p Promotes trophoblast cell survival, migration, and invasion and contributes topreeclampsia [78]
miR-424 Regulates trophoblast differentiation [79]
miR-494 Inhibits MSCs proliferation and angiogenesis [80]
miR-675 Regulates placental trophoblast cell proliferation [81]
Placenta-derived circulating microRNA
C14MC cluster Identified in the circulation of pregnancy women [82]
C19MC cluster Identified in exosome and released from human primary trophoblast; upregulatedin preeclamptic plasma; increased at early gestational age in circulation [83–85]
miR-127, miR-134, and
miR-498 cluster Uniquely correlated in the maternal and fetal circulation [82]
miR-135b, miR-141,
miR-149, and
miR-299-5p
Detected in maternal plasma during pregnancy and decreased in postdelivery
plasma [86]
Uterine microRNA
Let-7a, let-7b Induction on the process of embryo invasion during implantation; graduallyincreased in uteri to inhibit uterine stromal cell proliferation [87, 88]
miR-34b, miR-34c,
and miR-223 Overexpressed in spontaneous term labor [89]
miR-96, miR-219-5p,
and miR-375
Differentially expressed during prereceptive and receptive phase; regulator of
progesterone receptor [90]
mmu-miR-101a and
mmu-miR-199a∗ Regulate critical gene for implantation [91]
miR-199a/miR-214 Decreased in laboring myometrium and in an inflammatory preterm labor mousemodel [92]
miR-200 Implicated in uterus of preterm labor; involved in progesterone/progesteronereceptor pathway [93, 94]
miR-222 Regulates endometrial stromal cells (ESCs) differentiation [95]
their possible regulatory role in normal and complicated
pregnancies. Until now, studies of placenta-specific miRNAs
in the regulation of pregnancy are very limited focusing
only on the basic biological characteristics. Using high-
throughput profiling array and quantitative PCR, abundant
expression of C19MC members was located in the primary
human trophoblasts [83]. Moreover, cluster members of
C19MC were also shown to be abundantly expressed in
the placenta-derived mesenchymal stromal cells (PDMSC),
suggesting a potential regulatory role in the stem/progenitor
cells [99]. Furthermore, the C19MC members are shown
to be temporally expressed. For instance, placenta-specific
miRNAs, including miR-141 and C19MC family, were differ-
entially expressed in various development steps to meet the
different regulatory demands of pregnancy [100, 101].
Recently, the implication and possible regulation of these
miRNAs in normal and complicated pregnancywere revealed
partly. It was demonstrated that placenta-specific miRNAs,
miR-141 and miR-519d-3p (a member of C19MC), regulate
trophoblast cell proliferation, invasion, migration, and inter-
cellular communication [24, 27, 32]. Furthermore, Keniry
and colleagues demonstrated that overexpression of placenta-
exclusive miR-675 inhibited embryonic and extraembryonic
cell proliferation [34]. Notably, underexpression of four
C19MC members, miR-517a, miR-517b, miR-518b, and miR-
519a, was observed in complete hydatidiform moles (CHM)
[31]. Likewise, seven members of C19MC cluster, miR-518b,
miR-1323, miR-516b, miR-515-5p, miR-520h, miR-519d, and
miR-526b, were significantly downregulated in the placenta
of FGR patients and four of them (miR-518b, miR-1323,
miR-520h, andmiR-519d) were confirmed as FGR-associated
placenta-specific miRNA [28]. Furthermore, placenta-
specific miR-141 was identified to target pleiomorphic
adenoma gene 1 (PLAG1), an important regulator of insulin-
like growth factor 1 (IGF-1) that contributes to FGR [25].
3.2. Placenta-Associated MicroRNA. Placenta-associated
miRNAs are expressed ubiquitously in placenta and other
tissues. Like placenta-specific miRNAs, the placenta-
associated miRNAs show different expression profiles in
various gestational ages of trophoblast cells, placental tissue,
and maternal plasma. A total of 45 miRNAs were identified
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to be differentially expressed in the trophoblast cells of first-
and third-trimester placentas with 58% of these microRNAs
being placenta-associated [100]. Recent study on miRNA
profiles in human placenta identified 191 differentially
expressed microRNAs between first and third-trimester
placentas, including both placenta-specific and placenta-
associated microRNAs [102]. More importantly, this study
revealed that oncogenic, angiogenic, and antiapoptotic
miRNAs were dominantly expressed in the first-trimester
placentas, whereas expression of miRNAs related to cell
differentiation and tumor suppression was predominant in
the third-trimester placentas. Furthermore, in the maternal
plasma, a substantial amount of placental-associated
miRNAs was differently expressed during the first-, second-,
and third-trimester gestation [103].
3.2.1. Placenta-Associated MicroRNAs Response to Altered
Inflammation andHypoxia Condition in Pregnancy. Different
expression of miRNAs in the placenta during gestation
depends on regulatory demand of the physiological change,
such as inflammation and hypoxia [104, 105]. Let-7 functions
downstream of NF-𝜅B signaling pathway and negatively reg-
ulates IL-6 expression. Strong expression of let-7was detected
in the placenta and amnion, implying the possible regulation
on placental inflammation [36]. Similarly, miR-181a blocks
the activation of TGF-𝛽 signaling pathway and enhances
expression of IL-6; thus increased expression of miR-181a in
the placenta attenuates the immunosuppressive properties
of mesenchymal stem cells and contributes to the abnormal
pregnancy [63]. On the other hand, the miR-148/152 family
negatively regulates innate immune responses, mediating
immune tolerance to facilitate a healthy pregnancy [56, 57].
Since the placenta is relatively hypoxic in the early stage
and pathological condition of pregnancy [106, 107], placenta-
associated miRNAs also respond to this hypoxic challenge.
Interestingly, although hypoxia treatment did not affect the
global miRNA biosynthetic pathway in primary trophoblast,
the individual miRNA exhibited different expression patterns
under hypoxia [108]. A set of seven placenta-associated miR-
NAs, miR-93, miR-205, miR-224, miR-335, miR-424, miR-
451, and miR-491, were differentially expressed in primary
trophoblasts exposed to hypoxia andmiR-205 was confirmed
to target an important placental development factor, MED1
[51]. In cigarette smoke-exposed placenta, miR-16, miR-21,
andmiR-146a were significantly downregulated [39]. Further
studies confirmed that placenta-associated miRNAs regu-
late mitochondrial electron transport and renin-angiotensin
system adaptation to hypoxia. HIF-responsive miR-210 was
increased in hypoxic placenta which compromised mito-
chondrial electron transport chain function and energy
metabolism [69]. In antenatal maternal hypoxia (AMH),
the expression of placenta-associated miRNAs, miR-199b,
miR-27a, and miR-429, was reduced to allow an increase of
some important renin-angiotensin system factors that help
placental adaptation to hypoxia [47].
3.2.2. Placenta-Associated MicroRNAs Regulate Pregnancy-
Associated Cellular Activities. Many placental miRNAs were
identified as the regulators of pregnancy-related trophoblasts
and endothelium cellular activities. Members of the miR-
17∼92 cluster and its paralogs, miR-106a∼363 andmiR-106b∼
25, were significantly downregulated to facilitate syncytiotro-
phoblast differentiation [41]. Knockdown of global miRNA
synthesis and individual miRNA, such as miR-675, enhanced
trophoblast proliferation [18, 81]. Reversely, some miRNAs
were upregulated to enable trophoblast proliferation, migra-
tion, and invasion. For example, overexpression ofmiR-378a-
5p and miR-376c enhanced these processes [77, 78]. So far,
only a handful of miRNAs, including miR-424 [79], miR-
101 [52], miR-18a [46], miR-335 [50], miR-137 [55], and miR-
155 [61], have been implicated in trophoblast dysfunction
through various targets, including endothelial nitric oxide
synthase (eNOS) and soluble vascular endothelial growth
factor receptor 1 (sVEGFR-1 or sFlt-1).
Angiogenesis is another critical physiological activity in
the placenta during early pregnancy [13]. MiRNA profiles in
porcine placenta of different gestational age revealed altered
expression of some angiogenic-associated miRNAs, such as
miR-92, miR-17, and miR-27 [42]. In preeclampsia patients,
miR-126, a proangiogenic factor which correlates with VEGF
expression, was decreased [53]. On the contrary, miR-15b,
which negatively regulates angiogenesis in endothelial cells,
was shown to be increased in preeclamptic placentas [38].
3.2.3. Placenta-Associated MicroRNA in Pregnancy Compli-
cations. Since placenta-associated miRNAs are important
pregnancy regulators, the aberrant expression of these miR-
NAs is associated with various disorders of pregnancy.
Microarray profiling and further quantitative PCR analysis
revealed that miRNAs are differentially expressed in the
placenta and circulation of preeclamptic women. The first
study was published in 2007 where the group identified two
differentially expressed miRNAs between preeclamptic and
normal placentas [109]. Two years later, two studies using a
microarray approach identified seven and thirty-four differ-
entially expressedmiRNAs in preeclamptic placentas, respec-
tively [65, 67]. Recently, more placenta-associated miRNAs
have been found to be dysregulated in preeclamptic placental
tissue [110–112]. However, results from these studies are
elusive, even though similar approaches have been employed.
Due to the complexity of placenta composition and the differ-
ent gestational age upon sample collection, identifiedmiRNA
profiles can vary or present completely opposite results
between studies, for example, miR-195 [65–67]. Other stud-
ies, using next generation sequencing, determined different
miRNA expression profiles in the circulation of preeclampsia
and healthy pregnant women. Dysregulated expression of
over 29 miRNAs was observed in the plasma or serum of
preeclamptic placentas, including both placenta-specific and
placenta-associated circulating miRNAs [113, 114]. Like the
placental studies, these results are confusing and conflicting,
but, on the other hand, they also confirmed the implication
of miRNAs in the pathogenesis of preeclampsia and provided
potential miRNA candidates for further research.
3.2.4. miR-155 and miR-210 in the Pathogenesis of Pregnancy
Complications. Currently, only a handful placenta-associated
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miRNAs have been characterized for their function and
downstream targets in preeclampsia. Among these, miR-
155 and miR-210 are the most extensively examined ones.
Using preeclamptic placental tissue, the first study revealed
that miR-155 targeted and downregulated angiogenic factors,
thus contributing to the pathogenesis of preeclampsia [62].
Cheng and colleagues found thatmiR-155 was downregulated
in the preeclamptic patient endothelial cells. Further study
identified another critical preeclamptic pathogenic factor,
angiotensin II type 1 receptor, as a target of miR-155 [58].
In addition, miR-155 was linked to the trophoblast function,
including proliferation, invasion, and differentiation [59, 60].
Recently, miR-155 was shown to modulate eNOS expression
in trophoblast cells [61]. Another highly studied miRNA,
miR-210, was first identified in trophoblast cells as an iron
metabolism regulator responding to hypoxia stress and impli-
cated in the defective placentation [71]. Later, miR-210 was
confirmed to be upregulated in preeclampsia, resulting in
negative regulation of trophoblast cellmigration and invasion
[68, 75]. A recent study further identified its function in the
modulation of mitochondrial respiration in placenta which
contributes to preeclampsia [74]. Other studies revealed
that miR-210 modulates inflammation pathway, potassium
channel, and thrombospondin in order to contribute to
preeclampsia [70, 72, 73].
3.2.5. Other MicroRNAs in the Pathogenesis of Pregnancy
Complications. Apart from these two miRNAs, there are
many other miRNAs that are associated with preeclampsia.
For instance, miR-325 was elevated in the preeclamptic
patients and correlated with the patient blood pressure [76].
Notably, miRNAs related to the dysregulation of trophoblast
and stem cell function are also associated with preeclamp-
tic pathophysiology. MiR-378a-5p, miR-195, and miR-29b,
which regulate trophoblast cell proliferation, invasion,migra-
tion, and angiogenesis, were dysregulated in preeclamptic
placentas [48, 64, 78]. Recent study further confirmed the link
between mesenchymal stem cells (MSCs) related miRNAs
and pregnancy complications. MiRNA expression profile in
MSCs derived from serve preeclamptic patients showed sig-
nificant differences compared to healthy controls [115]. MiR-
494 inhibited MSCs proliferation and angiogenesis potential
[80], whereas miR-30a attenuated MSCs-mediated immune
response [44]. Furthermore, miRNAs that regulate impor-
tant physiological signaling pathways are also implicated
in preeclampsia. For example, angiogenesis-associated miR-
NAs, miR-17, miR-20a, and miR-20b, together with miR-21
which negatively regulates hydrogen sulfide generation, were
significantly increased in preeclamptic placentas [45, 116].
Placenta-associated miRNAs are also implicated in other
pregnancy complications, such as small-for-gestational age
(SGA), FGR, or IUGR. Although no difference was identified
in the miRNA profiles between SGA patients and control,
seven miRNAs were identified to be differentially expressed
between combined SGA/preeclampsia and control placentas
[109]. Similar studies using maternal FGR plasma confirmed
that individual miRNA expression in the FGR and con-
trol patients exhibited no difference. However, a total 1.8-
fold elevation in expression of a selected placenta-specific
and placenta-associated miRNA group was noticed [51].
Furthermore, individual miRNAs have been implicated in
SGA patients. For example, placental angiogenic-associated
miRNAs, miR-16 and miR-21, were markedly decreased in
the SGA placentas, suggesting an additive effect in SGA
pathogenesis [40].
In addition, placenta-associated miRNAs are implicated
in some maternal-related pregnancy disorders, for example,
preterm birth and abortion. Mayor-Lynn and colleagues ana-
lyzed the miRNA expression profiles between preterm and
normal term placentas. They identified twenty differentially
expressed miRNAs, including some well-known preeclamp-
tic or SGA-associated miRNAs [37]. In early pregnancy loss,
placental expression of miR-17 and 19b was downregulated
compared to the matched healthy controls [43]. MiR-133a
was shown to be overexpressed in the recurrent spontaneous
abortion (RSA) patient villi that led to the downregulation
of HLA-G [54]. Moreover, in the placenta accreta patients,
miR-34a expression was decreased in trophoblast cells and
the suppression of miR-34a increased trophoblast invasive
potential [49].
3.3. Placental-Derived CirculatingMicroRNA. Since miRNAs
are known to be released into circulation [22], efforts have
been made to identify the expression profiles of these miR-
NAs in maternal circulation and explore their diagnostic
potential [66, 113].
The placental-specific C19MC members were first dis-
covered in the maternal blood and proved to be released
from the trophoblasts via exosomes [83]. Upregulation of
circulating C19MC miRNAs was identified as a consequence
of preeclampsia onset [85]. Furthermore, Kotlabova and
colleagues tested the expression of some known placental-
specificmiRNAs and found sevenmembers of C19MC cluster
in the plasma [84]. In a follow-up study, expression of
these seven microRNAs was increased in the circulation of
women who were at early gestational age and later developed
pregnancy disorder [117]. Interestingly, work from the same
group demonstrated the downregulation of some C19MC
miRNAs in the placenta of pregnancy-related complications
[118]. In a recent study, profile of circulating placental-specific
miRNAs has been comprehensively identified [82]. Notably,
circulating placenta-specific miRNA clusters, miR-498 (46
individual microRNAs), miR-127 (8 individual microRNAs),
andmiR-134 (41 individualmicroRNAs), fell within the range
of C19MC and C14MC clusters. Furthermore, this study
identified unique expression pattern of miRNA clusters in
the maternal and fetal circulation, but not in the circulation
of men or nonpregnant women. Interestingly, the miRNA
fingerprints/profiles between primary isolated trophoblast
cells and trophoblast cell lines display major differences,
implying possible miRNA transportation and exchange from
other cell types [100].
3.3.1. Placenta-Derived Circulating MicroRNA as Biomarker.
Placenta-derived circulating miRNAs were initially intro-
duced as biomarkers for pregnancy monitoring. The miRNA
expression profiles in maternal plasma before and after
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parturition were analyzed and differently expressedmiRNAs,
including many placental-associated miRNAs, were further
confirmed by qPCR [119]. Interestingly, four of the most
abundant placental miRNAs, miR-141, miR-149, miR-299-
5p, and miR-135b, were also detectable in the maternal
plasma during pregnancy and followed by decrease after
delivery [86]. To confirm the biomarker potential, expression
profiles of these circulating miRNAs in the blood of pregnant
and nonpregnant women, under different pathophysiological
conditions, have been studied. In the serum of pregnant
women, miRNAs associated with placenta were significantly
elevated compared to nonpregnant women and their expres-
sion levels correlated with pregnancy stages [120]. Moreover,
a group of selected hypoxia-regulated and placenta-specific
miRNAs elevated 1.84-fold in the plasma of womenwith FGR
[51]. Importantly, the expression of these selected miRNAs
in the FGR women placenta was reduced when compared to
normal pregnant women, suggesting the reverse correlation
of miRNA expression in the circulation and placenta. How-
ever, the diagnostic potential of placental-derived miRNA is
still debatable with the recent evidence that the expression of
four members of C19MC did not show significant difference
between FGR and normal pregnancy [28]. It seems that a
miRNA pool rather than individual miRNAs has a defined
role as a biomarker. In addition,maternal circulatingmiRNAs
can be used as potential biomarker in not only the pregnancy-
related disorders but also fetal diseases, for example, fetal
congenital heart defects (CHD) [121].
4. Uterine MicroRNA
Uterus is a major female reproductive organ where fetus
develops during gestation.There is no doubt that themiRNAs
expressed in this organ are important for a healthy pregnancy.
First of all, global effect of the uterine miRNAs in pregnancy
was evaluated by knockdown ofDicer. In human endometrial
stromal cells (hESCs), knockdown of Dicer caused decrease
in decidualization marker and altered organization of actin
filaments [122]. Although knockdown of Dicer only had
a minor effect on the decidualization, 43 miRNAs were
identified to be differentially expressed in decidualized hESCs
compared to nondecidualized hESCs. Conditional knockout
of Dicer in mouse uterine epithelium and stroma led to
female sterility due to a small and significantly defective
uterus [123]. Moreover, uterine miRNA expression profiles
in the embryo implantation, term labor, and delivery were
intensively analyzed. Hu and colleagues identified 8 differ-
entially expressed miRNAs in the mouse uterus between
implantation sites and interimplantation sites [124]. Further-
more, a group of 62miRNAswere found to be dysregulated in
the uterus between activation and delayed implantation [42].
Moreover, the expression of 226 miRNAs in human uterine
cervix has been characterized and three miRNAs, miR-223,
miR-34b, and miR-34c, were overexpressed in patients with
spontaneous term labor [89].
4.1. Uterine MicroRNA Regulates Pregnancy Process. The
function of individual uterine miRNA in pregnancy was
revealed only partially. Early report in 2007 demonstrated
that two uterine miRNAs, mmu-miR-101a and mmu-miR-
199a∗, posttranscriptionally regulate a gene critical for
implantation [91]. Three years later, another well-established
cancer-associated miRNA, let-7a, was examined for the tem-
poral and spatial expression in the uteruswhere the induction
of let-7a was observed on the embryo invasion process [88].
Another member of let-7 family, let-7b, was found to be
associated with preimplantation stages in epithelial cells as
well as in uterus to inhibit uterine stromal cell proliferation
[87]. Moreover, a microarray study identified 49 differentially
expressed miRNAs between the noninduced endometrial
stromal cells (ESCs) and induced ESCs [95]. One of these
miRNAs, miR-222, regulates ESCs differentiation by direct
targeting of cyclin-dependent kinase.
In another study, miRNAs were demonstrated to be
important regulators of progesterone/estrogen signaling
pathways. A cancer-associated miRNA family, miR-200, was
implicated in uterus of both human andmouse preterm labor
and served as progesterone/progesterone receptor- (PR-)
mediated regulators [93]. Follow-up study discovered that
miR-200a also directly targets STAT5b, a transcriptional
repressor of the progesterone-metabolizing enzyme, and
facilitates the progress to labor [94]. Another miRNA cluster,
miR-199a/miR-214, was significantly decreased in laboring
myometrium of pregnant mice and human and in a preterm
labor mouse model [92]. Additionally, in rhesus monkeys,
a set of endometrial miRNAs were differentially expressed
during secretory phases and at least three miRNAs, miR-
96, miR-375, and miR-219-5p, were the direct regulator of
progesterone receptor [90]. On the contrary, progesterone or
estrogen stimulation alters expression of uterine miRNA. In
assisted reproduction cycles, the expression of miRNAs in
the endometrium was differentially regulated with 3–5 days
of progesterone treatment after retrieval (Zhao et al., 2012).
5. Maternal-Fetal MicroRNA Communication
Successful establishment of pregnancy requires coordination
and interactions of maternal and fetal genes, proteins, and
essential nutrients [125]. Growing evidence showed that
inherited maternal miRNAs in the fetus are essential for fetal
development. In mouse, the loss of maternal inheritance of
miRNAs by specific deletion of Dicer in maturing oocyte
caused the failure of the first cell division (Tang et al., 2007).
Perturbing of the maternally inherited small nucleolar RNA
(snoRNAs) and miRNAs resulted in embryonic lethality and
developmental abnormalities of both embryo and placenta
in mouse [126]. Maternal environmental and physiological
factors can directly affect fetal miRNA expression, meaning
that dysregulation of miRNA expression may lead to the
fetal defects or even lifelong consequences.Maternal cigarette
smoking during pregnancy downregulates cell growth and
expression of developmental related miRNAs, miR-16, miR-
21, and miR-146a, in the placenta [39]. Maternal low protein
diet in mice altered the expression of mmu-miR-27a, mmu-
miR-27b, and mmu-miR-330 which regulate brain renin-
angiotensin system in the fetal offspring (Goyal et al., 2010).
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Figure 3: The mutual communication of miRNAs between fetus and mother in the pregnancy may link to most pregnancy-associated
maternal and fetal disorders. The aberrant exchange of fetal and maternal miRNAs during pregnancy may even lead to lifelong problems
in the fetus and mother.
Moreover, maternal undernutrition amended the expression
of fetal aortic miRNAs, which target the extracellular matrix
remodeling and angiogenic factors in rat [15].
Moreover, fetal DNA and RNA, including miRNA, are
presented in the maternal circulation and serve as important
diagnostic tool for healthy pregnancy and fetal disease [127].
Previously, these fetal DNAs and RNAs were thought to
be byproducts of fetal cell debris. However a recent study
revealed that these small molecules have biological impli-
cations. MiRNAs released from cell surface and carried by
exosome and exocytosis may act as mediators of cell-to-
cell communication (Miura et al., 2010). These miRNA-
containing exosomes can effectively communicate between
different cell types and tissues under pathophysiological con-
ditions and are actively involved in various cellular activities
[128, 129].
Unfortunately, there are no reports on fetomaternal
interaction of miRNAs. However, the possible regulatory
roles of maternal miRNAs in fetal development and mater-
nal pregnancy-associated disorders have been proposed
[130]. It is evident that some pregnancy-associated maternal
disorders, such as preeclamptic-related renal disease and
pregnancy-induced hypertension, relieve their symptoms
after parturition. Therefore, the fetal-origin substance is
believed to be the root of these disorders [131]. These
substances were initially proposed to be cells and DNA
[132]. However, they are recently proved to be fetal RNAs,
including mRNA and miRNA [86, 133, 134]. Despite the lack
of functional characterization, the potential regulatory role of
these fetal-maternal trafficking miRNAs is widely accepted.
Essentially, the ectopic expression of these miRNAs may
be linked to most pregnancy-associated maternal and fetal
disorders (Figure 3).
6. Conclusions and Future Perspectives
Pregnancy is a complex and precisely regulated process. Loss
of the balance betweenmultiple physiological factors, such as
oxygen concentration and inflammation, causes disorders or
complications. For instance, the chronic hypoxia condition
in the pathological placenta damages endothelium, leading
to myocardial and microvascular dysfunctions, which is
believed to be an initiating event of preeclampsia and IUGR
[135, 136]. MiRNA as a “fine-tuner” is the best candidate
for this kind of precise regulation. Indeed, the microarray
data using placental and uterine tissue from different stages
of pregnancy or pregnancy with complications suggested
various miRNA expression patterns. The ability to suppress
rather than degrade targetmRNAmakesmiRNAs an effective
tool for spatial and temporal regulation of gene expression
in pregnancy and fetal development. Furthermore, the wide
target range of 60% mammalian mRNAs ensures the impor-
tance of miRNA in the regulation of most physiological and
pathological processes (Friedman et al., 2009). Particularly,
in the regulation of pregnancy, miRNAs are shown to be
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actively involved in TGF and progesterone/estrogen signal-
ing pathways, immune tolerance, inflammation, hypoxia,
fetus development, preeclampsia, and IUGR. Thus, we can
speculate that many other miRNAs which relate to the
fundamental cellular and tissue activities will also play roles
in the regulation of pregnancy.
The function of these pregnancy-related miRNAs is still
elusive. Current data of miRNA expression patterns, even
in the similar experimental and sampling conditions, can
be significantly different. Despite the controversy in the
literature, current studies still confirm that miRNAs are
involved in many aspects of pregnancy and its disorders.
MiRNAs were demonstrated to contribute to the immune
tolerance in pregnancy, mesenchymal cell differentiation,
and angiogenesis. Several miRNAs are shown to be the
regulators in trophoblast cells proliferation, migration, and
invasion, and the dysregulated expression of these miRNAs
was demonstrated in the tissues of preeclampsia or IUGR.
However, there are many other aspects that are largely
limited, such as fertilization, implantation, cleavage, decid-
ualization, gestation, and parturition. Placenta is the most
studied tissue type and very important fetal-maternal organ.
Unfortunately, uterus or other pregnancy-related organs have
been less extensively studied but are no less important.
Collectively, current studies on pregnancy-associated miR-
NAs are primitive with the main focus on trophoblast and
mesenchymal stem cells, while stromal and endothelial cells
that are essential to placental vasculature and angiogenesis
have been ignored.
Another important but less studied subject is the circu-
lating miRNA. Successful pregnancy requires the interaction
and communication betweenmaternal and fetal factors. Cur-
rent studies aremainly focusing on the biomarker potential of
these miRNAs and the regulatory and biological functions of
these miRNAs in pregnancy and its disorders have not being
proposed [134]. Considering the fact that many pregnancy-
associated disorders disappear after giving birth, exchange
of maternal-fetal substance, especially miRNAs, could be the
key to understand the pregnancy disorders.
AlthoughmiRNAs are proposed to be important diagnos-
tic markers and therapeutic targets, current applications of
these miRNAs are very limited. A recent study suggested that
serum miRNA assessment in the first trimester of pregnancy
showed no predictive value in early onset preeclampsia [137].
Themain reason for this is the complexity of miRNA biology,
leading to contradiction in the literature. A study compared
eight previously published array data sets with their own
microarray data and revealed a total of 138 differentially
expressed miRNAs in preeclamptic placenta. However, only
14% of these miRNAs were seen in more than one study
and the results agreed in the direction of change [138]. In
addition, miRNA expression profiling in maternal peripheral
blood and placental tissue within the same group of patients
is completely altered and the expression profile changes in
different gestational ages [118, 139]. Such contradiction may
arise due to the different time point or position of sample col-
lection and even different human population. Some miRNAs
were suggested to be only strongly expressed during narrow
time windows [140], while others were expressed oppositely
in different ethnic groups [141]. Taken together, miRNA
studies in pregnancy and its associated disorders are still in
the primary stage. Nevertheless, the potential application of
pregnancy-associated miRNAs in the medical diagnosis and
treatment of pregnancy-associated disorders is promising.
Future studies are guaranteed to enrich our understanding of
pregnancy-associated disorders and provide novel diagnostic
and therapeutic targets.
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